Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01247610 : Adult Outcome of Children With Attention-deficit/Hyperactivity Disorder
PhaseN/A
AgesMin: 17 Years Max: 24 Years
Eligibility
Inclusion Criteria:

1. Persistent ADHD combined type (Group 1, n=30): Subjects who have persistent diagnosis
of ADHD, combined type, at adulthood according to the DSM-IV diagnostic criteria and
who have same-sex unaffected siblings are included. If more than 30 subjects meet the
inclusion criteria, the subjects with more severe ADHD symptoms based on the ASRS and
K-SADS ratings will be included.

2. Unaffected sibling (Group 2, n=30): The same sex and handedness unaffected siblings
of Group 1 will be recruited. They need to be re-assessed by psychiatric interview to
confirm no lifetime diagnosis of ADHD.

3. Good response to MPH (Group 3, n=30): Subjects whose ADHD symptoms meet the DSM-IV
symptom criteria at adulthood and who either have DAT1 genes (around 10% of Taiwanese
children with ADHD15) or demonstrate good response to MPH based on clinical interview
were recruited for offand on-stimulant DSI and resting state fMRI assessments.

4. Non-ADHD (Group 4, n=30): Among healthy controls without lifetime ADHD, the controls
who do not have any lifetime psychiatric disorders and who do not have impaired
neuropsychological function will be included. The control subjects will be matched
for the age, gender, and handedness of Group 1.

Exclusion Criteria:

- These subjects will be excluded from the study if they have any of the following
criteria: (1) Comorbidity with DSM-IV-TR diagnosis of pervasive developmental
disorder, schizophrenia, schizoaffective disorder, delusional disorder, other
psychotic disorder, organic psychosis, schizotypal personality disorder, bipolar
disorder, depression, severe anxiety disorders or substance use; (2) With
neurodegenerative disorder, epilepsy, involuntary movement disorder, congenital
metabolic disorder, brain tumor, history of severe head trauma, and history of
craniotomy; and (3)With visual or hearing impairments, or motor disability which may
influence the process of MRI assessment. In addition, if the control subjects have
ODD or CD, they will be excluded.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01247610      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740